TY  - GEN
AU  - Pérez-Belmonte, Luis M.
AU  - Ricci, Michele
AU  - Sanz-Cánovas, Jaime
AU  - Cobos-Palacios, Lidia
AU  - López-Carmona, María D.
AU  - Ruiz-Moreno, M. Isabel
AU  - Millán-Gómez, Mercedes
AU  - Bernal-López, M. Rosa
AU  - Jansen-Chaparro, Sergio
AU  - Gómez-Huelgas, Ricardo
PY  - 2021
DO  - 10.3390/jcm10092013
UR  - http://hdl.handle.net/20.500.12105/18335
AB  - Canagliflozin is a sodium-glucose co-transporter 2 inhibitor that reduces glycemia as well as the risk of cardiovascular events. Our main objective was to analyze antidiabetic treatment de-intensification and the glycemic efficacy of replacing...
LA  - eng
PB  - Multidisciplinary Digital Publishing Institute (MDPI)
KW  - De-intensification
KW  - Efficacy
KW  - Canagliflozin
KW  - Heart failure
KW  - Type 2 diabetes
KW  - Capacidad de respuesta
KW  - Eficacia
KW  - Canagliflozina
KW  - Insuficiencia cardíaca
KW  - Diabetes mellitus tipo 2
KW  - Hipoglucemiantes
KW  - Hypoglycemic Agents
KW  - Metformin
KW  - Diabetes Mellitus, Type 2
KW  - Insulins
KW  - Hyperglycemia
KW  - Hospitalization
KW  - Sodium
KW  - Glucose
KW  - Retrospective Studies
KW  - Heart Failure
KW  - Therapeutics
TI  - De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study
TY  - research article
ER  -